2017
DOI: 10.5603/cj.a2016.0093
|View full text |Cite
|
Sign up to set email alerts
|

Short- and mid-term outcome of transcatheter aortic valve implantation in patients with advanced age

Abstract: (Cardiol J 2017; 24, 4: 358-363)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
5

Relationship

3
2

Authors

Journals

citations
Cited by 6 publications
(7 citation statements)
references
References 13 publications
(15 reference statements)
0
7
0
Order By: Relevance
“…Conventional aortic valve replacement is the gold standard for the treatment of aortic valve stenosis. However, TAVI has emerged and proved itself as a credible alternative for high-risk patients and patients in advanced age [ 1 , 13 ]. The latest meta-analysis had shown the safety and efficacy of TAVI when compared to the standard surgical treatment [ 14 ].…”
Section: Discussionmentioning
confidence: 99%
“…Conventional aortic valve replacement is the gold standard for the treatment of aortic valve stenosis. However, TAVI has emerged and proved itself as a credible alternative for high-risk patients and patients in advanced age [ 1 , 13 ]. The latest meta-analysis had shown the safety and efficacy of TAVI when compared to the standard surgical treatment [ 14 ].…”
Section: Discussionmentioning
confidence: 99%
“…General anesthesia or deep sedation was used during the procedures. The TTE monitoring was performed and a temporary pacemaker was inserted from the jugular vein for rapid pacing and as prevention of iatrogenic atrioventricular block consequences [19].…”
Section: Methodsmentioning
confidence: 99%
“…[ 5 ] Transcatheter aortic valve implantation (TAVI) has currently become an alternative treatment for severe AS patients who are inoperable or with very high surgical risk. [ 6 , 7 ] In the 2017 guidelines of the American heart association/American college of cardiology (AHA/ACC), it is clearly pointed out TAVI is recommended for AS patients with high-risk surgical operations (stage D), and is a reasonable alternative to SAVR for medium-risk AS patients (stage D). [ 8 ]…”
Section: Introductionmentioning
confidence: 99%
“…However, age, as an independent risk factor of perioperative mortality and morbidity for TAVI, [ 7 ] don’t be discussed in the 2017 guidelines of AHA/ACC. [ 9 , 10 ] The majority of TAVI patients are senile in the United States, with the median age of them being about 80 year [ 11 ] and approximately 16% of them being ≥90 years.…”
Section: Introductionmentioning
confidence: 99%